natgillin/translations-raw huggingface dataset:
Like all medicines, FORCALTONIN can have side effects. 
Kot vsa zdravila ima lahko tudi FORCALTONIN neželene učinke.
PHARMACEUTICAL FORM Solution for injection Clear colourless solution 
FARMACEVTSKA OBLIKA Raztopina za injiciranje Prozorna brezbarvna raztopina
PHARMACEUTICAL FORM AND CONTENTS Solution for injection - Pack of 10 doses: 
Raztopina za injiciranje - škatla z 10 odmerki:
Peak plasma concentrations are attained within the first hour of administration. 
Maksimalna koncentracija v plazmi se doseže prvo uro po dajanju zdravila.
METHOD AND ROUTE(S) OF ADMINISTRATION For subcutaneous (SC), intramuscular (IM) or intravenous (IV) injection. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Za subkutano (s.c.), intramuskularno (i.m.)
In severe or emergency cases, intravenous infusion with up to 10 IU/kg body weight in 500ml 0.9% w/v sodium chloride solution may be administered over a period of at least 6 hours. 
V hudih ali nujnih primerih smemo dati bolniku intravensko infuzijo z do 10 IE/kg telesne mase v 500 ml natrijevega klorida 9 mg/ml (0,9 %) raztopine za injiciranje, v trajanju najmanj 6 ur.
Driving and using machines: 
Vpliv na sposobnost upravljanja vozil in strojev:
The recommended dose is 100 International Units (15 micrograms of salmon calcitonin) daily, or 50 International Units (7.5 micrograms salmon calcitonin) twice daily, for 2 to 4 weeks, by subcutaneous or intramuscular injection. 
Priporočeni odmerek je 100 mednarodnih enot (15 mikrogramov lososovega kalcitonina) na dan ali 50 mednarodnih enot (7,5 mikrograma lososovega kalcitonina) dvakrat na dan za 2 do 4 tedne, s subkutanim ali intramuskularnim injiciranjem.
Serum calcium levels may be transiently decreased to below normal levels following administration of calcitonin, notably upon initiation of therapy in patients with abnormally high rates of bone turnover. 
Serumska raven kalcija lahko po tem, ko bolnik dobi kalcitonin, zlasti še na začetku zdravljenja pri bolnikih z nenormalno visoko stopnjo kostne presnove, začasno pade pod normalno raven.
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially sodium free. 
To zdravilo vsebuje manj kot 1 mmol soli (23 mg) na dozo, t.j.
Read the package leaflet before use. 
Pred uporabo preberite navodila v škatli.
Calcitonin has not been studied in pregnant women. 
Vpliva kalcitonina med nosečnostjo niso preučevali.
The recommended dose is 100 International Units (15 micrograms of salmon calcitonin) once daily by subcutaneous or intramuscular injection. 
Priporočeni odmerek je 100 mednarodnih enot (15 mikrogramov lososovega kalcitonina) enkrat dnevno, s subkutanim ali intramuskularnim injiciranjem.
of injectable salmon calcitonin have been administered without adverse reactions, other than nausea and vomiting, and exacerbation of pharmacological effects. 
Posamezni odmerki (do 10.000 IE) lososovega kalcitonina za injiciranje so bili dani brez neželenih učinkov, razen slabosti in bruhanja ter poslabšanja farmakološkega učinka.
In severe or emergency cases, an intravenous infusion with 10 International Units per kilogram body weight in 500 ml 0.9% w/v sodium chloride solution may be given to you by your doctor or nurse over a period of 6 hours. 
V hudih ali nujnih primerih vam lahko zdravnik ali medicinska sestra da intravensko infuzijo z 10 mednarodnimi enotami na kg telesne mase, v 500 ml natrijevega klorida 9 mg/ml (0,9 %) raztopine za injiciranje, v trajanju 6 ur.
Keep this leaflet. 
Ne zamrzujte.
Any unused product must be discarded. 
Neporabljena zdravila zavrzite.
Acetic acid, glacial, sodium acetate trihydrate, sodium chloride and water for injections. 
Ocetna kislina, ledocet, natrijev actetat trihidrat, natrijev klorid in voda za injekcije.
Never take a double dose to make up for a missed dose. 
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnjega.
The Marketing Authorisation Holder for FORCALTONIN is Unigene UK Limited, 191 Sparrows Herne, Bushey Heath, Hertfordshire WD23 1AJ, UK. 
Imetnik dovoljenja za promet z zdravilom FORCALTONIN je Unigene UK Limited, 191 Sparrows Herne, Bushey Heath, Hertfordshire WD23 1AJ, Velika Britanija.
Each ampoule contains 100 IU (15 micrograms in 1.0 ml) of recombinant salmon calcitonin. 
Vsaka ampula vsebuje 100 IE (15 mikrogramov v 1,0 ml) rekombinantnega lososovega kalcitonina.
After first opening, the product should be used immediately. 
Zdravilo je treba uporabiti takoj, ko ste ga odprli.
The recommended starting dose is 100 International Units (15 micrograms of salmon calcitonin) every 6 to 8 hours by subcutaneous or intramuscular injection. 
Priporočeni začetni odmerek je 100 mednarodnih enot (15 mikrogramov lososovega kalcitonina) vsakih 6 do 8 ur, s subkutanim ali intramuskularnim injiciranjem.
MARKETING AUTHORISATION HOLDER Unigene UK Limited, 191 Sparrows Herne, Bushey Heath, Hertfordshire WD23 1AJ, UK 
IMETNIK DOVOLJENJA ZA PROMET Unigene UK Limited, 191 Sparrows Herne, Bushey Heath, Hertfordshire WD23 1AJ, Velika Britanija
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION FORCALTONIN 100 IU solution for injection 
IME ZDRAVILA IN POT(I) UPORABE FORCALTONIN 100 IE raztopina za injiciranje
An increased incidence of pituitary adenomas has been reported in rats given synthetic salmon calcitonin for 1 year. 
Pri podganah, ki so 1 leto prejemale sintetični lososov kalcitonin, so poročali o povečani pogostnosti adenoma hipofize.
Inform your doctor immediately if any of the above effects occur. 
Če pride do zgoraj opisanih učinkov, takoj obvestite svojega zdravnika, ki bo ustrezno ukrepal.
Most of the effects do not last long and disappear of their own accord. 
Večina teh učinkov ne traja dolgo in izgine sama od sebe. Preostale učinke, če ne izginejo, lahko zdravi vaš zdravnik.
If you are unsure whether you are allergic to salmon calcitonin, please discuss the matter with your doctor. 
Če niste prepričani, ali ste alergični na lososov kalcitonin ali ne, se o tem pogovorite s svojim zdravnikom, ki lahko opravi kožno testiranje, s katerim ugotovi, kako občutljivi ste na lososov kalcitonin.
If you have any questions about your treatment schedule, ask your doctor or nurse. 
O vsem, kar želite vedeti v zvezi z načrtom svojega zdravljenja, vprašajte zdravnika ali medicinsko sestro.
NAME OF THE MEDICINAL PRODUCT Forcaltonin 100 IU solution for injection 
IME ZDRAVILA Forcaltonin 100 IE raztopina za injiciranje
• dizziness 
• omotičnost.
The active substance of FORCALTONIN is recombinant salmon calcitonin. 
Zdravilna učinkovina v zdravilu FORCALTONIN je rekombinantni lososov kalcitonin.
Injectable calcitonin may cause transient dizziness (see 4.8. 
Kalcitonin za injiciranje lahko začasno povzroča omotičnost (glejte poglavje 4.8 Neželeni učinki), ki lahko poslabša odzivnost bolnika.
The other ingredients are acetic acid, glacial, sodium acetate trihydrate, sodium chloride and water for injections. 
Pomožne snovi so ocetna kislina, ledocet, natrijev actetat trihidrat, natrijev klorid in voda za injekcije.
METHOD OF ADMINISTRATION Read the package leaflet before use. 
POSTOPEK UPORABE Pred uporabo preberite navodila v škatli.
The treatment should be maintained until patients are fully mobilized. 
Odmerek lahko na začetku remobilizacije zmanjšamo na 50 IE na dan. Z uporabo zdravila je treba nadaljevati, dokler ni bolnik znova popolnoma mobiliziran.
LIST OF EXCIPIENTS Excipients: Acetic acid, glacial, sodium acetate trihydrate, sodium chloride and water for injections. 
SEZNAM POMOŽNIH SNOVI Pomožne snovi: ocetna kislina, ledocet, natrijev actetat trihidrat, natrijev klorid in voda za injekcije.
FORCALTONIN must be given by injection. 
FORCALTONIN dajemo bolnikom samo z injiciranjem.
Do not pass it on to anyone else. 
Zdravilo predpiše samo vam in ga ne smete dati drugim.
Your doctor may reduce the dose of FORCALTONIN after your condition has improved. 
Ko se vam stanje izboljša, vam zdravnik odmerek FORCALTONINa lahko zmanjša.
BEFORE YOU USE FORCALTONIN 
KAJ MORATE VEDETI, PREDEN BOSTE UPORABILI FORCALTONIN
It is recommended that you do not inject your medicine at exactly the same site each time you use it in order to avoid discomfort. 
Da bi se izognili tej neprijetnosti, svetujemo, da zdravila ne injicirate vedno na istem mestu.
FORCALTONIN 100 IU Solution for Injection, recombinant salmon calcitonin 
FORCALTONIN 100 IE raztopina za injiciranje rekombinantni lososov kalcitonin
The active substance is recombinant salmon calcitonin. 
Zdravilna učinkovina je rekombinantni lososov kalcitonin.
Hypercalcaemia of malignancy. 
Hiperkalciemija zaradi malignih obolenj.
twice daily for 2 to 4 weeks, administered subcutaneously or intramuscularly. 
Priporočeni odmerek je 100 IE na dan ali 50 IE dvakrat na dan, 2 do 4 tedne, dan subkutano ali intramuskularno.
Each ampoule of FORCALTONIN contains 1 ml of solution with 100 International Units (IU) of the active substance. 
Vsaka ampula zdravila FORCALTONIN vsebuje 1 ml raztopine s 100 mednarodnimi enotami (IE) zdravilne učinkovine, ki ustreza približno 15 mikrogramom rekombinantnega lososovega kalcitonina.
Renal and urinary disorders: Uncommon: diuresis 
Bolezni sečil Občasni: diureza
However, the clinical relevance of this finding is not known (see section 5.2) 
Presnovni očistek je dosti nižji pri bolnikih s končno odpovedjo ledvic kot pri zdravih osebah, vendar klinična pomembnost te ugotovitve ni znana (glejte poglavje 5.2).
FORCALTONIN should therefore not be given to pregnant women. 
Varnost uporabe med nosečnostjo ni znana, zato ni priporočljivo dajati FORCALTONIN nosečnicam.
Irritation at or around the injection site has been reported occasionally in patients treated with salmon calcitonin. 
Pri bolnikih, zdravljenih z lososovim kalcitoninom, so poročali o občasnem vnetju kože na mestu injiciranja ali okoli njega.
Immune system disorders: 
Bolezni imunskega sistema
Skin flushes (facial or upper body). 
Zelo pogosti: rdečica (na obrazu ali zgornjem delu telesa).
General characteristics of the active substance 
Splošne lastnosti zdravilne učinkovine
Tell your doctor or nurse immediately, if you notice any of the effects listed below. 
Če opazite katerega od spodaj navedenih učinkov, nemudoma obvestite svojega zdravnika ali medicinsko sestro.
Tell your doctor as soon as possible if you miss a dose of FORCALTONIN. 
Če pozabite vzeti odmerek FORCALTONINa, o tem čim prej obvestite zdravnika.
• skin rash 
• kožni izpuščaj,
Hypercalcemia of malignancy: 
Hiperkalciemija zaradi malignih obolenj
• Hypercalcaemia of malignancy 
• pri hiperkalciemiji zaradi malignih obolenj.
The product should be inspected visually for particulate matter and discoloration prior to administration. 
Zdravilo pred uporabo preglejte, ali so v njem vidni trdni delci in ali je prisotno razbarvanje.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING 
PODATKI NA ZUNANJI OVOJNINI ALI STIČNI OZ. PRIMARNI OVOJNINI, KADAR ZUNANJE NI
PACKAGE LEAFLET 
Bolezni prebavil
List of the names, pharmaceutical form, strength of the medicinal products, route of administration, applicants/ marketing authorisation holders in the Member States 
Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe, predlagateljev, imetnikov dovoljenj za promet z zdravilom v državah članicah
ATC code: N05A H03. 
Oznaka ATC: N05A H03.
Your doctor will tell you how many Olanzapine Teva tablets to take and how long you should continue to take them. 
Zdravnik vam bo povedal, koliko Olanzapin Teva tablet morate vzeti in kako dolgo naj bi jih jemali.
4042 Debrecen Hungary 
4042 Debrecen Madžarska
Teva Pharmaceutical Works Co. Ltd Pallagi út 13, 4042 Debrecen Hungary 
Teva Pharmaceutical Works Co. Ltd Pallagi út 13, 4042 Debrecen Madžarska
Parkinson's disease 
• Parkinsonovo bolezen
Tell your doctor or pharmacist if you are taking, have recently taken or might take use any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Do not use this medicine after the expiry date which is stated on the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake “EXP”.
- Medicines of this type may cause unusual movements mainly of the face or tongue. 
- Tovrstna zdravila lahko povzročijo nenavadne zgibke predvsem v mišicah obraza ali jezika.
The mean increase in olanzapine AUC was 52% and 108% respectively. 
Srednje povečanje AUC olanzapina je bilo 52 % oziroma 108 %.
If this happens after you have been given Olanzapine Teva tell your doctor. 
Če se vam to zgodi po tem, ko ste prejeli zdravilo Olanzapin Teva, povejte svojemu zdravniku.
Orodispersible tablet is the technical name for a tablet which dissolves directly in your mouth, so that it can be easily swallowed. 
Orodisperzibilna tableta je tehnično ime za tableto, ki se raztopi neposredno v ustih, tako da jo zlahka pogoltnete.
This leaflet was last revised in <{MM/YYYY}><{month YYYY}>. 
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}><{mesec LLLL}.>
With long-term exposure (at least 24 weeks), 89.4% gained ≥7%, 
Pri dolgoročni izpostavljenosti (najmanj 24 tednov) jih je 89,4 % pridobilo ≥ 7 %,
However, since patients with schizophrenia often present with acquired risk factors for venous thromboembolism all possible risk factors of VTE, e.g. immobilisation of patients, should be identified and preventive measures undertaken. 
Vendar, ker imajo bolniki s shizofrenijo pogosto prisotne pridobljene dejavnike tveganja za vensko tromboembolijo, je treba ugotoviti vse možne dejavnike tveganja za VTE, kot npr. imobilizacija bolnikov ter izvesti preventivne ukrepe.
A lower starting dose (5 mg/day) is not routinely indicated but should be considered for those 65 and over when clinical factors warrant (see section 4.4). 
Nižji začetni odmerek (5 mg na dan) ni rutinsko priporočen, vendar ga je treba upoštevati pri osebah, starih 65 let in več, kadar to upravičujejo klinični dejavniki (glejte poglavje 4.4).
Dementia-related psychosis and/or behavioural disturbances Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident. 
Psihoza, povezana z demenco, in/ali vedenjske motnje Olanzapin ni priporočljiv za uporabo pri bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
In these trials, patients were initially required to be stable on the lowest effective dose of anti-Parkinsonian medicinal products (dopamine agonist) and to remain on the same anti-Parkinsonian medicinal products and dosages throughout the study. 
V teh preskušanjih je bilo potrebno, da se je zdravstveno stanje bolnikov najprej ustalilo ob prejemanju najnižjega učinkovitega odmerka antiparkinsonskih zdravil (dopaminskih agonistov) ter da so ves čas študije prejemali ista antiparkinsonska zdravila v enakih odmerkih.
Clinically significant weight gain (≥7%) appears to occur more frequently in the adolescent population compared to adults with comparable exposures. 
(≥ 7 %) pojavlja pogosteje pri populaciji mladostnikov v primerjavi z odraslimi pri primerljivi izpostavljenosti.
- Tell the doctor if you or someone else in your family has a history of blood clots, as medicines like these have been associated with the formation of blood clots. 
- Če ste vi ali kdo iz vaše družine v preteklosti imeli krvne strdke, morate o tem obvestiti svojega zdravnika, saj lahko zdravila, kot je to, povzročijo nastanek krvnih strdkov.
Very common: Elevations of hepatic aminotransferases (ALT/AST; see section 4.4). 
Zelo pogosti: Zvišane ravni jetrnih aminotransferaz (ALT/AST; glejte poglavje 4.4)
In a retrospective observational cohort study, the risk of presumed sudden cardiac death in patients treated with olanzapine was approximately twice the risk in patients not using antipsychotics. 
V retrospektivni opazovalni kohortni študiji so ugotovili, da je bilo tveganje za domnevno nenadno srčno smrt pri bolnikih, ki so se zdravili z olanzepinom, približno dvakrat večje kot pri bolnikih, ki niso jemali antipsihotikov.
55.3%gained ≥15% and 29.1% gained ≥25% of their baseline body weight. 
55,3 % ≥ 15 % in 29,1 % ≥ 25 % od njihove osnovne telesne mase.
QT interval In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] 
V kliničnih preskušanjih so bila klinično pomembna podaljšanja QTc (QT korekcija Fridericia
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of ≥7% from baseline body weight in 39.9% of patients. 
Dolgoročno zdravljenje z olanzapinom (do 12 mesecev) za preprečevanje ponovnega pojava bolezni pri bolnikih z bipolarno motnjo je bilo povezano s povečanjem telesne mase za ≥ 7 % z osnove pri 39,9 % bolnikov.
The plasma protein binding of olanzapine was about 93% over the concentration range of about 7 to about 1000 ng/ml. 
Vezava olanzapina na plazemske beljakovine je bila okoli 93 % v razponu koncentracij od približno 7 do približno 1000 ng/ml.
Consult your doctor if your symptoms return but do not stop taking Olanzapine Teva unless your doctor tells you to. 
Če se simptomi povrnejo, se posvetujte s svojim zdravnikom, vendar ne prenehajte jemati zdravila Olanzapin Teva, če vam tega ne naroči vaš zdravnik.
It is important that you carry on taking Olanzapine Teva for as long as your doctor tells you. 
Pomembno je, da nadaljujete z jemanjem zdravila Olanzapin Teva tako dolgo, kot vam naroči zdravnik.
Olanzapine Teva orodispersible tablet should be placed in the mouth, where it will rapidly disperse in saliva, so it can be easily swallowed. 
Olanzapin Teva orodisperzibilno tableto naj se položi v usta, kjer se hitro dispergira v slini, tako da jo je mogoče brez težav pogoltniti.
Very common: Sedation (including: hypersomnia, lethargy, somnolence). 
Zelo pogosti: Sedacija (vključno s: hipersomnijo, letargijo, zaspanostjo)
Risk Management Plan (RMP) Not applicable. 
ZDRAVILA • Načrt za obvladovanje tveganj (RMP)
Alternatively, it may be dispersed in a full glass of water or other suitable beverage (orange juice, apple juice, milk or coffee) immediately before administration. 
Drug način uporabe je, da tableto dispergiramo v polnem kozarcu vode ali druge ustrezne pijače (pomarančni sok, jabolčno sok, mleko ali kava) neposredno pred zaužitjem.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 
Če vam je vaš zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
Olanzapine Teva tablets break easily, so you should handle the tablets carefully. 
Olanzapin Teva tablete se zlahka lomijo, zato z njimi ravnajte previdno.
In patients with Parkinson's disease Olanzapine Teva may worsen the symptoms. 
Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo Olanzapin Teva poslabša simptome.
The daily dose of Olanzapine Teva is between 5 mg and 20 mg. 
Dnevni odmerek zdravila Olanzapin Teva je med 5 mg in 20 mg.
You should not be given this medicine when breast-feeding, as small amounts of Olanzapine Teva can pass into breast milk. 
Ko dojite, tega zdravila ne smete jemati, ker lahko majhne količine zdravila Olanzapin Teva prehajajo v materino mleko.
Very rare side effects include serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). 
Zelo redki neželeni učinki vključujejo resne alergijske reakcije, kot je reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS - Drug Reaction with Eosinophilia and Systemic
Eastbourne, East Sussex, BN22 9AG United Kingdom 
Eastbourne, East Sussex, BN22 9AG Velika Britanija
The mean increase in olanzapine Cmax following fluvoxamine was 54% in female non-smokers and 77% in male smokers. 
Srednje zvišanje Cmax olanzapina po dajanju fluvoksamina je bilo 54 % pri ženskah nekadilkah in
Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking Olanzapine Teva and regularly during treatment. 
Vaš zdravnik mora opraviti krvni test za preiskavo sladkorja v krvi in nivo določenih maščob pred začetkom jemanja zdravila Olanzapin
LIST OF EXCIPIENTS Contains, among others, Lactose monohydrate. 
Med drugim vsebuje laktozo monohidrat.
There were more smokers among subjects with cirrhosis (4/6; 67%) than among subjects with no hepatic dysfunction (0/3; 0%). 
Med osebami s cirozo (4/6, 67 %) je bilo več kadilcev kot med osebami brez jetrne okvare (0/3, 0 %).
Contains among others: lactose, sucrose and aspartame (E951). 
Med drugim vsebuje: laktozo, saharozo in aspartam (E951).
You should take your Olanzapine Teva tablets once a day following the advice of your doctor. 
Olanzapin Teva tablete jemljite enkrat na dan, in sicer upoštevajte nasvet zdravnika.
In cases where dose increments of 2.5 mg are considered necessary, Olanzapine Teva film-coated tablets should be used. 
V primerih, kjer so nujna višanja odmerkov po 2,5 mg, je potrebno uporabljati Olanzapin Teva filmsko obložene tablete.
≥25% was common (2.5%). 
občasno (2,5 %).
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter. 
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z olanzapinom, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let.
Pharmacotherapeutic group: psycholeptics, diazepines, oxazepines, thiazepines and oxepines. 
Farmakoterapevtska skupina: psiholeptiki, diazepini, oksazepini, tiazepini in oksepini.
The frequency terms listed are defined as follows: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the data available). 
Našteti izrazi pogostnosti so definirani kot sledi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), ni znano (ocena ni možna iz danih podatkov).
The frequency terms listed are defined as follows: Very common (≥1/10), common (≥1/100 to <1/10). 
Našteti izrazi pogostnosti so definirani kot sledi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10).
Discontinuation symptoms7,12 
Odtegnitveni simptomi7, 12
(≥ 1.016 mmol/l-<1.467 mmol/l) to high (≥1.467 mmol/l). 
(≥ 1,016 mmol/l - < 1,467 mmol/l) na visoke (≥ 1,467 mmol/l).
Do not stop taking your tablets just because you feel better. 
Če ste prenehali jemati zdravilo Olanzapin Teva Ne prenehajte jemati tablet samo zato, ker se počutite bolje.
DRESS appears initially as flu like symptoms with a rash on the face and then with an extended rash, high temperature, enlarged lymph nodes, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia). 
Simptomi DRESS so ob nastopu sprva podobni simptomom gripe, z izpuščaji na obrazu, ki se nato razširijo drugam, povišano telesno temperaturo, povečanimi bezgavkami, povišano ravnijo jetrnih encimov ob krvnih preiskavah in povečanjem števila vrste belih krvnih celic (eozinofilija).
Brampton Road, Hampden Park Eastbourne, East Sussex, BN22 9AG United Kingdom 
Brampton Road, Hampden Park Eastbourne, East Sussex, BN22 9AG Velika Britanija
This medicine contains 2.25 mg/4.5 mg/6.75 mg/9 mg aspartame in each 5 mg/10 mg/15 mg/20 mg orodispersible tablet. 
To zdravilo vsebuje 2,25 mg/4,5 mg/6,75 mg/9 mg aspartam (E951) v vsaki 5-mg/10-mg/15-mg/20mg orodisperzibilni tableti.
- The use of Olanzapine Teva in elderly patients with dementia is not recommended as it may have serious side effects. 
- Uporabe zdravila Olanzapin Teva pri starejših bolnikih z demenco ne priporočamo, ker ima lahko resne neželene učinke.